Literature DB >> 10892669

Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium.

R Takahashi1, M A Talukder, M Endoh.   

Abstract

We performed experiments in rabbit ventricular papillary muscles loaded with aequorin to elucidate the mechanism of positive inotropic effect (PIE) of OR-1896, an active metabolite of levosimendan. The concentration-response curve (CRC) for OR-1896 was biphasic: PIE of OR-1896 reached a plateau at 10(-5) M (first phase), and the CRC became steeper at 10(-3) M and higher (second phase). Maximal response of the first phase was 11% of the maximal response to isoproterenol (ISOmax) and associated with an increase in Ca2+ transients of 5% of ISOmax. For a given degree of PIE, the increase in Ca2+ transients by OR-1896 was lower than that induced by elevation of [Ca2+]o. The PIE of OR-1896 was not associated with impairment of relaxation, and it was abolished by carbachol. In conclusion, OR-1896 has a PIE partly due to an increase in myofibrillar Ca2+ sensitivity that is exerted through crosstalk with signal transduction mediated by cyclic adenosine monophosphate (cAMP).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892669     DOI: 10.1097/00005344-200007000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

2.  Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

3.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

Review 4.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Authors:  Jaakko Puttonen; Sampo Kantele; Matti Kivikko; Sari Häkkinen; Veli-Pekka Harjola; Petri Koskinen; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 7.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.

Authors:  Z Papp; J Van Der Velden; A Borbély; I Edes; G J M Stienen
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

Review 9.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.

Authors:  Saila Antila; Matti Kivikko; Lasse Lehtonen; Jaan Eha; Aira Heikkilä; Pasi Pohjanjousi; Pertti J Pentikäinen
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.